Berry Global, PYLOTE Introduce Activated Rispharm™ at Pharmapack 2022 in Paris

The first-to-market multidose antimicrobial dropper to help prevent eye microbial infections for patients.

Activated Rispharm™, the first-to-market multidose antimicrobial dropper to help prevent eye microbial infections for patients, will be introduced at Pharmapack 2022 (18th & 19th May in Paris). Developed in a strategic commercial partnership between BERRY GLOBAL, a leading provider of innovative packaging and engineered products, and PYLOTE, a key player in industrial mineral chemistry, the solution will be presented on the Berry Global stand (A60). Activated Rispharm™ will also be submitted to the 2022 Pharmapack Awards and will be seen at the exhibition’s Innovation Gallery.

Pylote’s patented mineral technology – microspheres – is embedded into the resin masterbatch, and is fully recyclable, thus supporting efforts towards sustainability.  

Activated Rispharm™ offers significant benefits including:

Proven and certified antimicrobial mineral protection of dropper tip where over 85% of the contamination of the drops is found according to clinical study (Nentwich et al, Br J Ophthalmol 91(10): 1265-68). Proven and certified effectiveness against Adenovirus type 3 (conjunctivitis), Escherichia Coli, and Staphylococcus aureus. Allows patients to have hygienic applications for every use with a multidose dropper. Reduces the amount of plastic waste by 16 times for 1-month treatment compared to monodose solutions. No change in patient treatment methods.Fully compliant, stable, and biocompatible while certified non-irritant and non-cytotoxic technology (ISO10993:2010). No modifications required to packaging design or existing manufacturing/filling processes. Learn more about our range of healthcare packaging.